Peptide Therapeutics Forum 2020 (SCS online)

The event provides an innovative platform to exchange on the various aspects of drug development with a focus on peptides.

Similar to previous events in the framework of Basel Life, presentations highlight important new insights regarding the drug discovery of peptides including examples for successful development candidates. This forum should disseminate information on latest news in the broad field of therapeutic peptides and enable networking of interested parties from academia and industries.

Flyer Peptide Therapeutics Forum 2020

Link to the Program, Monday 17 August 2020

Link to the Program, Tuesday 18 August 2020

Confirmed Speakers:

• Prof. Jean-Louis Reymond, University of Bern, Switzerland, «The peptide chemical space as tool for discovery and optimization»
• Dr. Pottayil G Sasikumar, Aurigene Discovery Technologies Ltd, India, «Discovery of peptide inspired orally bioavailable drugs for cancer immunotherapy»
• Dr. Dominic Höpfner & Dr. Jürg Hunziker, Novartis Pharma AG, Switzerland, «Target fishing with peptide natural products by chemogenomics»
• Prof. Ali Tavassoli, University of Southampton, UK, «Platforms for the generation and high-throughput screening of Microcycle libraries for inhibitors of protein-protein interactions»
• Prof. Fernando Albericio, University of Kwazulu-Natal, South Africa, «Peptides from the Nature to the Laboratory»
• Dr. Sebastien Dutertre, CNRS University of Montpellier, France, «Backbone cyclization turns a venom peptide into a stable and equipotent ligand at both muscle and neuronal nicotinic receptors»
• Prof. Mandë Holford, Hunter College, New York, USA, «Venom Peptides Attack Cancer Using a Channelopathy Strategy»
• Prof. Annette Beck-Sickinger, University of Leipzig, Germany, «G protein coupled peptide receptors - State of the art and innovative therapeutic concepts»
• Dr. Hans Melo, Menten Biotechnology Labs, Canada, «Designing peptides on a quantum computer»
• Dr. Dominik Sarma, Belyntic, Germany, «Parallel manufacturing of AI-predicted peptide epitopes for vaccination against the SARS-CoV-2 virus»
• Dr. Simone Schadt, F. Hoffmann-La Roche AG, Switzerland, «Biotransformation of peptide drugs»
• Dr. Armin Bauer, Sanofi-Aventis Deutschland GmbH, Germany, «Synthesis and optimization of non-ribosomal peptide antibiotics»
• Prof. Stephan Urban, University of Heidelberg, Germany, «Can a peptide cure chronically infected Hepatitis B and D patients? Recent clinical results on Myrcludex B/bulevirtide»
• Dr. Christian Schwarz, NUMAFERM GmbH, Germany, «The white spot of biotechnology – medium to long chained peptides»
• Michael Wagner, Sanofi-Aventis Deutschland GmbH, Germany, «Chemical Probes for the Discovery and Development of Peptide Therapeutics»
• Dr. Theodosia Maina-Nock, Molecular Radiopharmacy, NCSR Demokritos, Greece, «Radiolabeled bombesin and gastrin analogs in cancer theranostics: Developments at NCSR "Demokritos"»
• Dr. Mike Pennington, AmbioPharm, USA, «Cell penetrating plant peptide targets Kv1.3 and inhibits effector memory T-cells»
• Dr. Joel P. Schneider, National Cancer Institute, USA, «Peptide-based materials for miRNA delivery and the treatment of mesothelioma»

Contact:

Forum Chairs:
Prof. Melpomeni Fani, Universitätsspital Basel
Prof. Roderich Süssmuth, TU Berlin
Dr. Thomas Vorherr, Novartis, Basel